Sprouts Farmers Market chief stores officer sells $48,491 in stock

Sprouts Farmers Market NASDAQ:SFM Chief Stores Officer Dustin Hamilton sold 346 shares of the company’s common stock on September 5, 2025, at a price of $140.15, for a total transaction value of $48,491. The $13.3 billion specialty grocery chain has shown robust performance, with its stock delivering a 34% return over the past year. According to InvestingPro analysis, the company maintains a GREAT financial health score, supported by strong profitability metrics.

Following the transaction, Hamilton directly owns 23,549 shares, which includes 13,758 shares of common stock and 9,791 restricted stock units. While this insider transaction represents a small portion of holdings, InvestingPro data reveals management has been actively buying back shares, demonstrating confidence in the company’s future. Get access to 10+ additional exclusive ProTips and comprehensive analysis through the Pro Research Report.

The sale was executed to cover the withholding tax liability incurred upon the vesting of restricted stock units, as mandated by Sprouts Farmers Market’s equity incentive plan. The stock currently trades at a P/E ratio of 28, with analysts maintaining positive earnings revisions for the upcoming period.

In other recent news, Sprouts Farmers Market reported stronger-than-expected second-quarter results, with same-store sales growth of 10.2%, surpassing analyst estimates of 9.0% and consensus expectations of 8.5%. This performance marked a 120 basis point sequential acceleration to 16.9% on a two-year stack basis. The company also announced a new $1 billion share repurchase program, replacing its previous authorization with approximately $143 million remaining. On the analyst front, Wells Fargo upgraded Sprouts Farmers Market from Equal Weight to Overweight, raising its price target to $180.00, citing growth potential despite concerns about decelerating comparable store sales growth. Barclays also upgraded the stock to Overweight, increasing the price target to $185.00, driven by confidence in the company’s multi-year growth trends and incremental sales drivers like the loyalty program and e-commerce operations. Meanwhile, UBS lowered its price target slightly to $180.00 but maintained a Neutral rating, highlighting supply chain impacts. Additionally, JPMorgan assumed coverage with a Neutral rating, setting a price target of $159.00, down from a previous target of $165.00, while acknowledging the company’s strong position in a health-conscious market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.